Global End Stage Renal Disease (ESRD) Therapy Market Research Report 2022

Table Of Contents

1 Report Overview

1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global End Stage Renal Disease (ESRD) Therapy Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Hemodialysis 1.2.3 Peritoneal Dialysis 1.2.4 Kidney Transplantation 1.3 Market by Application 1.3.1 Global End Stage Renal Disease (ESRD) Therapy Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Hospitals 1.3.3 Kidney Dialysis Centers 1.3.4 At Homes 1.3.5 Others 1.4 Study Objectives 1.5 Years Considered2 Global Growth Trends 2.1 Global End Stage Renal Disease (ESRD) Therapy Market Perspective (2017-2028) 2.2 End Stage Renal Disease (ESRD) Therapy Growth Trends by Region 2.2.1 End Stage Renal Disease (ESRD) Therapy Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 End Stage Renal Disease (ESRD) Therapy Historic Market Size by Region (2017-2022) 2.2.3 End Stage Renal Disease (ESRD) Therapy Forecasted Market Size by Region (2023-2028) 2.3 End Stage Renal Disease (ESRD) Therapy Market Dynamics 2.3.1 End Stage Renal Disease (ESRD) Therapy Industry Trends 2.3.2 End Stage Renal Disease (ESRD) Therapy Market Drivers 2.3.3 End Stage Renal Disease (ESRD) Therapy Market Challenges 2.3.4 End Stage Renal Disease (ESRD) Therapy Market Restraints3 Competition Landscape by Key Players 3.1 Global Top End Stage Renal Disease (ESRD) Therapy Players by Revenue 3.1.1 Global Top End Stage Renal Disease (ESRD) Therapy Players by Revenue (2017-2022) 3.1.2 Global End Stage Renal Disease (ESRD) Therapy Revenue Market Share by Players (2017-2022) 3.2 Global End Stage Renal Disease (ESRD) Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by End Stage Renal Disease (ESRD) Therapy Revenue 3.4 Global End Stage Renal Disease (ESRD) Therapy Market Concentration Ratio 3.4.1 Global End Stage Renal Disease (ESRD) Therapy Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by End Stage Renal Disease (ESRD) Therapy Revenue in 2021 3.5 End Stage Renal Disease (ESRD) Therapy Key Players Head office and Area Served 3.6 Key Players End Stage Renal Disease (ESRD) Therapy Product Solution and Service 3.7 Date of Enter into End Stage Renal Disease (ESRD) Therapy Market 3.8 Mergers & Acquisitions, Expansion Plans4 End Stage Renal Disease (ESRD) Therapy Breakdown Data by Type 4.1 Global End Stage Renal Disease (ESRD) Therapy Historic Market Size by Type (2017-2022) 4.2 Global End Stage Renal Disease (ESRD) Therapy Forecasted Market Size by Type (2023-2028)5 End Stage Renal Disease (ESRD) Therapy Breakdown Data by Application 5.1 Global End Stage Renal Disease (ESRD) Therapy Historic Market Size by Application (2017-2022) 5.2 Global End Stage Renal Disease (ESRD) Therapy Forecasted Market Size by Application (2023-2028)6 North America 6.1 North America End Stage Renal Disease (ESRD) Therapy Market Size (2017-2028) 6.2 North America End Stage Renal Disease (ESRD) Therapy Market Size by Country (2017-2022) 6.3 North America End Stage Renal Disease (ESRD) Therapy Market Size by Country (2023-2028) 6.4 United States 6.5 Canada7 Europe 7.1 Europe End Stage Renal Disease (ESRD) Therapy Market Size (2017-2028) 7.2 Europe End Stage Renal Disease (ESRD) Therapy Market Size by Country (2017-2022) 7.3 Europe End Stage Renal Disease (ESRD) Therapy Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries8 Asia-Pacific 8.1 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size (2017-2028) 8.2 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size by Country (2017-2022) 8.3 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia9 Latin America 9.1 Latin America End Stage Renal Disease (ESRD) Therapy Market Size (2017-2028) 9.2 Latin America End Stage Renal Disease (ESRD) Therapy Market Size by Country (2017-2022) 9.3 Latin America End Stage Renal Disease (ESRD) Therapy Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil10 Middle East & Africa 10.1 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Size (2017-2028) 10.2 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Size by Country (2017-2022) 10.3 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE11 Key Players Profiles 11.1 Fresenius 11.1.1 Fresenius Company Detail 11.1.2 Fresenius Business Overview 11.1.3 Fresenius End Stage Renal Disease (ESRD) Therapy Introduction 11.1.4 Fresenius Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.1.5 Fresenius Recent Development 11.2 DaVita 11.2.1 DaVita Company Detail 11.2.2 DaVita Business Overview 11.2.3 DaVita End Stage Renal Disease (ESRD) Therapy Introduction 11.2.4 DaVita Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.2.5 DaVita Recent Development 11.3 Baxter 11.3.1 Baxter Company Detail 11.3.2 Baxter Business Overview 11.3.3 Baxter End Stage Renal Disease (ESRD) Therapy Introduction 11.3.4 Baxter Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.3.5 Baxter Recent Development 11.4 Nipro 11.4.1 Nipro Company Detail 11.4.2 Nipro Business Overview 11.4.3 Nipro End Stage Renal Disease (ESRD) Therapy Introduction 11.4.4 Nipro Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.4.5 Nipro Recent Development 11.5 B. Braun 11.5.1 B. Braun Company Detail 11.5.2 B. Braun Business Overview 11.5.3 B. Braun End Stage Renal Disease (ESRD) Therapy Introduction 11.5.4 B. Braun Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.5.5 B. Braun Recent Development 11.6 Asahi Kasei 11.6.1 Asahi Kasei Company Detail 11.6.2 Asahi Kasei Business Overview 11.6.3 Asahi Kasei End Stage Renal Disease (ESRD) Therapy Introduction 11.6.4 Asahi Kasei Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.6.5 Asahi Kasei Recent Development 11.7 Nikkiso 11.7.1 Nikkiso Company Detail 11.7.2 Nikkiso Business Overview 11.7.3 Nikkiso End Stage Renal Disease (ESRD) Therapy Introduction 11.7.4 Nikkiso Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.7.5 Nikkiso Recent Development 11.8 WEGO 11.8.1 WEGO Company Detail 11.8.2 WEGO Business Overview 11.8.3 WEGO End Stage Renal Disease (ESRD) Therapy Introduction 11.8.4 WEGO Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.8.5 WEGO Recent Development 11.9 Newsol 11.9.1 Newsol Company Detail 11.9.2 Newsol Business Overview 11.9.3 Newsol End Stage Renal Disease (ESRD) Therapy Introduction 11.9.4 Newsol Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.9.5 Newsol Recent Development 11.10 Mayo Clinic 11.10.1 Mayo Clinic Company Detail 11.10.2 Mayo Clinic Business Overview 11.10.3 Mayo Clinic End Stage Renal Disease (ESRD) Therapy Introduction 11.10.4 Mayo Clinic Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.10.5 Mayo Clinic Recent Development 11.11 Guangdong Biolight 11.11.1 Guangdong Biolight Company Detail 11.11.2 Guangdong Biolight Business Overview 11.11.3 Guangdong Biolight End Stage Renal Disease (ESRD) Therapy Introduction 11.11.4 Guangdong Biolight Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.11.5 Guangdong Biolight Recent Development 11.12 Medtronic 11.12.1 Medtronic Company Detail 11.12.2 Medtronic Business Overview 11.12.3 Medtronic End Stage Renal Disease (ESRD) Therapy Introduction 11.12.4 Medtronic Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.12.5 Medtronic Recent Development 11.13 Sanxin Medtec 11.13.1 Sanxin Medtec Company Detail 11.13.2 Sanxin Medtec Business Overview 11.13.3 Sanxin Medtec End Stage Renal Disease (ESRD) Therapy Introduction 11.13.4 Sanxin Medtec Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.13.5 Sanxin Medtec Recent Development 11.14 Jafron Biomedical 11.14.1 Jafron Biomedical Company Detail 11.14.2 Jafron Biomedical Business Overview 11.14.3 Jafron Biomedical End Stage Renal Disease (ESRD) Therapy Introduction 11.14.4 Jafron Biomedical Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.14.5 Jafron Biomedical Recent Development 11.15 SWS Hemodialysis Care 11.15.1 SWS Hemodialysis Care Company Detail 11.15.2 SWS Hemodialysis Care Business Overview 11.15.3 SWS Hemodialysis Care End Stage Renal Disease (ESRD) Therapy Introduction 11.15.4 SWS Hemodialysis Care Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.15.5 SWS Hemodialysis Care Recent Development 11.16 Tianyi Medical 11.16.1 Tianyi Medical Company Detail 11.16.2 Tianyi Medical Business Overview 11.16.3 Tianyi Medical End Stage Renal Disease (ESRD) Therapy Introduction 11.16.4 Tianyi Medical Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022) 11.16.5 Tianyi Medical Recent Development12 Analyst's Viewpoints/Conclusions13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details